This inventor holds 1 USPTO granted patent. Top assignee: Shire Human Genetic Therapies, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Richard Fahrner: Innovator in CNS Delivery of Lysosomal Enzymes
Introduction
Richard Fahrner is an accomplished inventor based in Boxford, MA (US). He has made significant contributions to the field of genetic therapies, particularly in the treatment of lysosomal storage diseases. His innovative work focuses on methods and compositions for the central nervous system (CNS) delivery of essential enzymes.
Latest Patents
Richard Fahrner holds a patent for "Methods and compositions for CNS delivery of iduronate-2-sulfatase." This invention provides compositions and methods for the effective treatment of lysosomal storage diseases. The patent includes a stable formulation for direct CNS intrathecal administration, comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant specifically for the treatment of Hunter's Syndrome. He has 1 patent to his name.
Career Highlights
Fahrner is associated with Shire Human Genetic Therapies, Inc., where he applies his expertise in developing innovative therapies. His work has been pivotal in advancing treatment options for patients suffering from genetic disorders.
Collaborations
Richard has collaborated with notable colleagues, including Gaozhong Zhu and Kris Lowe, to further enhance the impact of his research and innovations.
Conclusion
Richard Fahrner's contributions to the field of genetic therapies exemplify the importance of innovation in medical science. His work in CNS delivery systems is paving the way for more effective treatments for lysosomal storage diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile